Payer Financing of Digital Health Technology
Updated: Sep 23
The Payer Budget Is a Calendar, a Competition, and a Risk Decision
A health plan can like a technology, believe the problem is real, and still decline to buy. The failure is often attributed to a slow sales cycle or a conservative buyer. More often, the proposal entered the organization at the wrong moment, asked for the wrong kind of money, or left the internal champion to solve too many unanswered questions.
Payer financing is not a single budget. It is a sequence of planning cycles, regulatory commitments, capital decisions, and tradeoffs among projects that rarely compete on product category alone. A startup improves its odds when it understands that system and designs the commercial process around it.
Budget timing begins before the sales conversation
Health plans build many commitments months before a vendor sees a formal procurement process. Regulated products and pricing, next-year operating plans, capital requests, and employer renewals create a recurring rhythm.
The webinar describes a common pattern. During the second quarter, plans develop product pricing and next-year budgets. In the third quarter, approvals and final decisions advance. The fourth quarter is often devoted to product rollout and closing the current year. In the first quarter, leaders review prior-year financial performance and enrollment; when results disappoint, adjustable administrative and capital spending can be among the first areas constrained.
The exact cadence varies by line of business. Medicare, individual, and small-group products follow regulatory submissions. Medicaid rate and procurement calendars differ by state. Self-funded employer offerings can offer more flexibility but remain connected to renewal timing. The commercial lesson is stable: a buyer may have authority to sponsor a solution but no open budget window to fund it.
Entering the pipeline during the third quarter can position a project for the next planning cycle. Arriving late in the fourth quarter with an unplanned implementation may mean nurturing the relationship until the following year. Asking about timing early is not giving up leverage. It prevents both sides from pretending a decision can occur on a schedule the organization cannot support.
Capital includes more than the vendor fee
A proposal’s visible price is only part of the buyer’s investment. A plan also considers technology integration, security review, legal negotiation, clinical oversight, implementation staff, communications, training, analytics, reporting, and the opportunity cost of assigning scarce people to the project.
That is why a “free” pilot can still be expensive. Even with no vendor invoice, internal teams must configure the program, move data, recruit members, monitor performance, and decide whether to scale. If those requirements are unclear, the buyer assumes risk.
A strong proposal makes the internal resource model explicit. It identifies required functions, estimates time, distinguishes one-time from ongoing work, and shows how the vendor will reduce the burden. Lower implementation friction can matter as much as a lower price when two projects promise similar results.
This also expands the competitive set. A digital health company is not only competing with other diabetes, navigation, or maternal-health vendors. It may be competing with a core-system upgrade, a compliance requirement, a call-center initiative, an internal build, or a project in an entirely different clinical category. The budget committee compares business cases across the enterprise
The first yes only earns the next review
An initial champion is essential, but it is not the purchase decision. A payer typically moves a proposal through multiple stakeholders before a final committee approves or rejects it.
Clinical leaders examine evidence and safety. Finance tests assumptions and budget fit.
Operations considers workflow and staffing. Technology and security review integration and risk. Legal evaluates contracting and regulatory exposure. Product teams assess differentiation and customer demand. Network, quality, compliance, marketing, and customer-experience teams may also participate.
The vendor should help the champion navigate this system. That means providing a concise business case, implementation plan, security materials, data requirements, evidence summary, pricing logic, and answers tailored to each stakeholder. The goal is not to flood the organization with collateral. It is to make the next internal conversation easier.
Questions about process should begin early: who else must approve, what committee makes the final decision, what evidence will finance require, when are budgets locked, and what has caused similar projects to fail? A faster “no” can be valuable if it reveals that the buyer lacks timing, ownership, or a viable funding source.
Hard benefits travel farther than hopeful savings
Payers distinguish between benefits they can realize with confidence and outcomes that may emerge over time. Replacing a current expense, automating measurable manual work, or reducing a defined unit cost can create a hard benefit. Future utilization reductions may be valuable but depend on engagement, clinical effectiveness, attribution, and time.
The payer will reconstruct the ROI rather than accept a vendor’s headline. Assumptions should therefore be transparent, conservative, and connected to the buyer’s own population. A business case gains credibility when it explains where savings come from, which costs increase, how results will be measured, and what happens if engagement is lower than expected.
Urgency also matters. A regulation, employer commitment, quality gap, or immediate operational failure can elevate a project because the cost of doing nothing is clear. A solution with a strong theoretical ROI but no deadline may remain behind mandatory work.
The strongest value story combines economics with de-risking: a clear problem, a measurable effect, a realistic implementation, and a financing structure that limits exposure while evidence develops.
Reframe the offer when the first model fails
The webinar’s restricted-recipient case shows how deal design can change the answer. A solution addressing narcotic misuse was initially offered through a per-member-per-month model with uncertain savings, operational and legal concerns, and poor timing. The proposal was restructured around individual cases, internal concerns were resolved, implementation burden fell, and the timing aligned with an open-enrollment need.
Nothing fundamental about the underlying problem changed. The financing unit, risk allocation, and operating plan did.
A prior-authorization automation example produced the opposite result. The resource requirements were unclear, hard savings were not established, authorization volume might increase, and the request arrived outside the budget cycle. Automation alone did not create a financeable project.
These cases suggest a practical sequence: identify the buyer’s current process, model the work required, choose a pricing unit that matches measurable value, secure stakeholder confidence, and align the decision with an available budget window.
Sell into the plan’s obligations and customers
Some of the most useful financing signals are public. Regulations reveal mandatory work. Medicaid requests for proposals show what states will reward. Employer renewal priorities indicate what a commercial plan’s customers want. Payer accelerators and investment arms can provide structured entry points, though they are crowded and should not be mistaken for a contract.
Organization size changes the navigation strategy. National plans may have defined innovation teams and formal processes but significant competition and complexity. Regional plans may offer stronger access and less crowded pipelines, although the correct entry point may be less obvious. Small plans can have simpler structures while depending on a limited number of busy senior leaders.
In every case, the vendor should ask for directions rather than assume the org chart. The objective is to understand how the plan commits money, people, and attention.
Payer sales become more predictable when financing is treated as part of product-market fit. The company is not selling only a solution. It is selling a business case that must survive a calendar, compete for capital, pass a risk review, and remain executable after the contract is signed.
About the Speakers
Geoff Bartsh
CEO of LCA Strategy and Consulting
Geoff is a healthcare executive with significant P&L and business-line leadership experience. He has guided organizations through market transformation, worked with boards and regulators, and developed growth strategies amid uncertainty. Connect with Geoff on LinkedIn.
Demi Radeva, MSc
Founder and Chief Strategist at Akros Advisory
Demi has more than a decade of experience across Medicaid, Medicare, and Commercial health plans, including leadership roles at UnitedHealthcare and Optum. She now advises HealthTech companies on reimbursement, payer strategy, market access, and commercialization. Connect with Demi on LinkedIn.
Comments